gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · AMRXHealthcarePharmaceuticals

Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)

$19.95−1.29%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$19.95▲ 75.77% in range
Nov 4, 2025Low $11.35 · High $21.51Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Amneal Pharmaceuticals closed at $19.95 on Nov 4, down 1.29%, 7.3% below its 52-week closing high. Volume of 7.2M shares was 1.71× its 20-day average (above normal).

Split-adjusted performance: -1.7% over one month, +46.5% over six months, +78.2% over one year.

In the quarter ended Jun 30, 2026, revenue was $796.20M, up 9.9% from a year earlier, with a net margin of 7.2%.

Short interest was 14.1M shares at the Oct 15 settlement, up 24.7% from the prior report (8.2% of float, 3.7 days to cover).

Market cap$6.95B348.3M shares
Revenue · quarter$796.2M+9.9% YoY
Diluted EPS$0.18+157.1% YoY
P/E · TTM44.2×P/S 2.2×
Net margin7.2%Gross 42.0%
Dividend yieldNone
52-week range11.20 – 21.51−7.3% from high
Volume7.2M1.71× 20-day avg
Volatility · 60d38.0%Annualised
Short % of float8.2%3.7 days to cover
Net cash-$2.54BCash $127.6M
Next earnings—Not scheduled
Split-adjusted performance
1W −5.6%1M −1.7%3M +10.4%6M +46.5%YTD +58.3%1Y +78.2%3Y +414.2%5Y +273.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum92
Revenue growth55
Net margin76
Value (low P/E)26
Size92

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short14.1M+24.7% vs prior
Days to cover3.7Settled Oct 15
% of float8.2%
Short vol. 10d58.9%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
AMRXAmneal Pharmaceuticals$19.95−1.29%+46.5%+9.9%7.2%44.2$6.95B
AXSMAxsome Therapeutics$137.00−1.87%−38.5%+51.9%−5.0%—$7.18BCompare
ORKAOruka Therapeutics$101.41+1.87%+45.3%———$6.71BCompare
IONSIonis Pharmaceuticals$40.15−0.67%−47.8%−40.7%−42.8%—$6.67BCompare
KNSAKiniksa Pharmaceuticals International$96.12+3.03%+65.1%+58.1%16.6%68.9$7.55BCompare
RYTMRhythm Pharmaceuticals$110.68+28.04%+14.6%+46.9%−70.7%—$7.62BCompare
LGNDLigand Pharmaceuticals$316.13+0.83%+35.9%−31.8%−36.2%122.9$6.32BCompare
MIRMMirum Pharmaceuticals$96.97+11.42%−11.9%+39.6%−22.0%—$6.30BCompare
ALKSAlkermes$45.89+0.44%+29.9%+21.8%3.4%—$7.70BCompare

News about Amneal Pharmaceuticals

All news →
AMRX Q3 Earnings & Sales Beat Estimates, FY'26 Guidance RaisedZacks Investment Research · 16h ago▲ PositiveAmneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Top EstimatesZacks Investment Research · 1d ago▲ PositiveAmneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?Zacks Investment Research · Oct 27, 2026▲ PositiveWill Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research · Oct 26, 2026▲ PositiveAmneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?Zacks Investment Research · Sep 17, 2026Neutral

Quick answers

What does Amneal Pharmaceuticals do?
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE.
What is AMRX's market cap?
$6.95B, based on the Nov 4 close of $19.95.
What is AMRX's P/E ratio?
44.2× trailing-twelve-month earnings of $157.36M.
Does Amneal Pharmaceuticals pay a dividend?
No regular cash dividend has been paid in the last year.
How much of AMRX is sold short?
14.1M shares, 8.2% of float, as of Oct 15, 2026.
What sector is AMRX in?
Healthcare, in the Pharmaceuticals industry.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

8,500 employeesListed May 7, 2018amneal.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology